A day after announcing an agreement with a Chinese firm to develop and commercialize a new drug cocktail treatment for chronic hepatitis C, TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) provided more details of the link-up.
TaiGen and YiChang HEC ChangJiang Pharmaceutical Co Ltd (HEC, 宜昌東陽光長江藥業) have agreed to establish a joint venture to produce a treatment cocktail of two oral direct-acting antiviral agents (DAA) — TaiGen’s furaprevir (TG-2349), a NS3/4A protease inhibitor, and HEC’s yimitasvir (DAG-181), a NS 5 protein inhibitor.
The joint venture is to be established before the end of this year with capitalization of 680 million yuan (US$102 million), of which 348.4 million yuan would be provided by HEC in cash in exchange for a 51 percent stake.
TaiGen will receive a 49 percent stake for its licensing rights to TG-2349, which is appraised at about US$50 million, company officials said yesterday at a news conference in Taipei.
The company is expecting to book profits of US$20 million for its 49 percent stake before the second half of next year, TaiGen vice president of finance Richard Lu (呂理堅) said.
The agreement also stipulates that when the new cocktail completes its second-phase clinical trials in China, TaiGen would sell a 9 percent-portion of its stake in the joint venture to HEC for about another US$40 million, Lu added.
However, the conditions for the US$40 million sale would be contingent upon whether the new cocktail is able to achieve a sustained viral response rate of more than 90 percent in its second-phase study, Lu said.
The new cocktail has received fast-track review designation from Chinese regulators, and is scheduled to hit the market in two to three years, TaiGen chief operating officer Hsu Ming-chu (許明珠) said.
The outcome of scientific due diligence and animal testing on drug-to-drug interactions combining TG-2349 and DAG-181 have been favorable, Hsu said.
“We were approached by HEC last May to explore a partnership and we found the company to be a capable partner in terms of funding as well as the viability of its new drug,” Hsu said, adding that TaiGen had rejected a number of prospective candidates.
The joint venture will allow TaiGen to begin commercializing new drugs earlier in the development phase. In the past its revenue streams came from out-licensing its late-stage development drugs.
Currently available DAA treatments for hepatitis C can cost as much as US$90,000 for a 12-week regimen, but the joint venture’s new drug would be priced significantly lower, Hsu said.
The lower pricing, and the enlisting of a Chinese partner represent an advantage in gaining approval from Beijing regulators, who are looking to control China’s healthcare costs and improve access to treatments, Hsu said.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) last week recorded an increase in the number of shareholders to the highest in almost eight months, despite its share price falling 3.38 percent from the previous week, Taiwan Stock Exchange data released on Saturday showed. As of Friday, TSMC had 1.88 million shareholders, the most since the week of April 25 and an increase of 31,870 from the previous week, the data showed. The number of shareholders jumped despite a drop of NT$50 (US$1.59), or 3.38 percent, in TSMC’s share price from a week earlier to NT$1,430, as investors took profits from their earlier gains
In a high-security Shenzhen laboratory, Chinese scientists have built what Washington has spent years trying to prevent: a prototype of a machine capable of producing the cutting-edge semiconductor chips that power artificial intelligence (AI), smartphones and weapons central to Western military dominance, Reuters has learned. Completed early this year and undergoing testing, the prototype fills nearly an entire factory floor. It was built by a team of former engineers from Dutch semiconductor giant ASML who reverse-engineered the company’s extreme ultraviolet lithography (EUV) machines, according to two people with knowledge of the project. EUV machines sit at the heart of a technological Cold
TAIWAN VALUE CHAIN: Foxtron is to fully own Luxgen following the transaction and it plans to launch a new electric model, the Foxtron Bria, in Taiwan next year Yulon Motor Co (裕隆汽車) yesterday said that its board of directors approved the disposal of its electric vehicle (EV) unit, Luxgen Motor Co (納智捷汽車), to Foxtron Vehicle Technologies Co (鴻華先進) for NT$787.6 million (US$24.98 million). Foxtron, a half-half joint venture between Yulon affiliate Hua-Chuang Automobile Information Technical Center Co (華創車電) and Hon Hai Precision Industry Co (鴻海精密), expects to wrap up the deal in the first quarter of next year. Foxtron would fully own Luxgen following the transaction, including five car distributing companies, outlets and all employees. The deal is subject to the approval of the Fair Trade Commission, Foxtron said. “Foxtron will be
INFLATION CONSIDERATION: The BOJ governor said that it would ‘keep making appropriate decisions’ and would adjust depending on the economy and prices The Bank of Japan (BOJ) yesterday raised its benchmark interest rate to the highest in 30 years and said more increases are in the pipeline if conditions allow, in a sign of growing conviction that it can attain the stable inflation target it has pursued for more than a decade. Bank of Japan Governor Kazuo Ueda’s policy board increased the rate by 0.2 percentage points to 0.75 percent, in a unanimous decision, the bank said in a statement. The central bank cited the rising likelihood of its economic outlook being realized. The rate change was expected by all 50 economists surveyed by Bloomberg. The
RSS